Innovent Biologics and Eli Lilly’s Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin’s Lymphoma (cHL) Patients

 Innovent Biologics and Eli Lilly’s Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin’s Lymphoma (cHL) Patients

Innovent Biologics and Eli Lilly’s Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin’s Lymphoma (cHL) Patients

Shots:
  • The approval is based on ORIENT-1 study results assessing Tyvyt in patients with 2L+ Hodgkin’s lymphoma
  • The ORIENT-1 study resulted in effective complete response rates for CT + radiotherapy in patients
  • Tyvyt is an IgG4 mAb, which helps in binding with PD-1 in T cells further blocking PD-L1. In 2015, Innovent Biologics and Eli Lilly collaborated to jointly develop and commercialize Tyvyt in China

Click here to read full press release/ article | Ref: Innovent Biologics | Image: ChinaKnowledge

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post